Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Dow's 379-Point Drop Led By Losses For UnitedHealth, NVIDIA Corp. Shares
Express News | Shares of Some Obesity Drug Developers Fall After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial
Amgen Inc. Stock Sheds 4.3%, Underperforms Competitors
NVIDIA Corp., Amgen Share Losses Lead Dow's 200-Point Fall
Top SA Quant-rated Healthcare Stocks as Q1 Earnings Unfold
Fund Update: FERGUSON WELLMAN CAPITAL MANAGEMENT, INC Added 170,577 Shares of AMGEN ($AMGN) to Their Portfolio
Trump Targets Medicare Price Negotiations in New Executive Order
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408, Maintains Buy Rating
Uncertainty looms, which biotech stocks in the U.S. are expected to break through? Goldman Sachs provides the answer.
Goldman Sachs suggests focusing on companies that are less affected by tariffs and policy risks, such as Vertex Pharmaceuticals (VRTX.US) and Alnylam Pharmaceuticals (ALNY.US).
The Trump administration has initiated a "tariff investigation" in the pharmaceutical sector, and the "safe haven" appeal of Indian pharmaceutical stocks has almost completely disappeared.
Indian pharmaceutical stocks are facing a large-scale sell-off, impacted by the dual blows of the Trump tariff investigation and a slowdown in capital flow.
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350
UBS Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $319
Amgen Is Maintained at Neutral by UBS
Amgen Analyst Ratings
Dow's 500-Point Rally Highlighted By Gains In Shares Of Apple, Amgen
Viking, Structure, Metsera on a Tear as Pfizer Drops Obesity Pill